Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIATE: Biphasic Insulin Aspart 70/30 vs Insulin Glargine in Type 2 Diabetes
NCT00598793Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2002
- Primary completion
- Mar 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Insulin aspart + insulin aspart protamine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin at 28 weeks. Started Nov 2002; status: completed.
02
Drugs
Insulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00598793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00598793.